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Abstract The bare-metal Tryton Side Branch (SB)
StentTM (Tryton Medical, Durham, NC, USA) is used with
a drug-eluting stent (DES) in the main branch (MB) to treat
bifurcation lesions. It is argued that a drug-eluting Tryton-
version is needed to improve clinical outcomes, although
previous registries have shown good clinical results. More
insights in neo-intimal hyperplasia (NIH) growth patterns
of the Tryton treatment strategy are needed to decide if and
where to drug-coat the stent. Ten patients returned for
follow-up angiography (mean follow-up time 393 ± 103
days) and optical coherence tomography (OCT) pullbacks
from the MB were obtained in all patients and from the SB
in six patients. A per-strut analysis showed an uncovered
strut rate of 0.7 % and an incompletely-apposed strut rate
of 0.8 %. Most incompletely-apposed struts were found at
the bifurcation region, in the luminal half facing towards
the SB. Mean NIH thickness in the proximal MB, distal
MB and SB were 0.14 ± 0.11, 0.19 ± 0.11, and 0.34 ±
0.19 mm, respectively, with a variety of growth patterns
observed in the SB. We found good vascular healing of the
DES in the MB, while healing was less favourably in the
SB part. Furthermore, we observed a variety of NIH growth
patterns in this SB part and more studies are needed to
investigate the relation between growth patterns and clin-
ical outcomes.
Keywords Coronary artery disease  Percutaneous
coronary intervention  Coronary bifurcation lesion 
Bifurcation lesion  Bifurcation stent  Tryton stent 
Optical coherence tomography  Three-dimensional optical
coherence tomography
Introduction
Coronary bifurcation lesions accounts for approximately
15 % of all percutaneous coronary interventions (PCI)
performed [1]. Percutaneous treatment of bifurcation
lesions remains technically challenging and is associated
with an increased risk of in-stent restenosis and stent
thrombosis, when compared with non-bifurcation lesions
[2, 3]. Therefore, several dedicated bifurcation devices,
such as the Tryton side branch (SB) stentTM (Tryton
Medical, Durham, NC, USA) have been developed to
improve clinical outcomes after PCI of bifurcation lesions.
The Tryton stent is a SB stent which is used in combination
with a regular drug-eluting stent (DES) in the main branch
(MB) and could be considered as a modified culotte tech-
nique [4]. Although being a bare-metal stent (BMS), pre-
vious observational studies have consistently shown low
target lesion revascularization rates of *4 % at
6–12 months of follow-up (FU) [5–9]. It is argued whether
a drug-eluting version of this device would further improve
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clinical outcomes. Some argue that two DES in close
proximity will increase stent thrombosis rates [10, 11],
others are convinced drug-elution is essential to prevent
excessive SB neo-intimal hyperplasia (NIH). Therefore,
more insights in NIH growth patterns of the Tryton treat-
ment strategy are needed. Optical coherence tomography
(OCT) has a higher resolution compared to intravascular
ultrasound (*20 vs*200 micron) and is therefore suitable
to perform a per-strut analysis evaluating strut apposition,
strut coverage, and per-strut NIH growth. We present a
1-year FU study evaluating the NIH growth patterns of the
Tryton strategy by using quantitative coronary angiography
(QCA) and OCT analyses.
Methods
Setting
Our center, the Academic Medical Center—University of
Amsterdam, is a large referral hospital with an annual PCI
volume of *2,000 procedures. All PCIs and adjunctive
pharmacological treatment were performed according to
the current guidelines.
Device
The Tryton stent has been extensively described elsewhere
[4, 12]. It is a balloon-expendable cobalt-chromium slot-
ted-tube BMS. The stent is placed from the proximal MB
into the SB using four radio-opaque markers, after which a
regular DES is placed from the proximal to distal MB
through the Tryton stent. The Tryton technique could be
considered as a facilitated culotte technique. The stent
design consists of three zones (distal SB zone, transition
zone, and proximal MB zone) providing optimal scaf-
folding of the SB while minimizing the amount of metal in
the MB. It is recommended to end the procedure with final
kissing balloon inflation.
Study design
The study cohort consisted of ten patients in whom PCI of a
bifurcation lesion was performed using the Tryton stent in
our center between January 2011 and April 2012. Patients
were asked to return for angiographic FU with OCT after
9 months. All patients who received a Tryton during the
study period were eligible for inclusion except for patients
who already underwent a re-PCI involving the target vessel
within 9 months. Written informed consent was obtained
from all patients prior to the repeat angiography. After repeat
coronary angiography was performed, using the same views
as before and after the initial procedure, OCT pullbacks were
performed in both MB and SB. OCT pullbacks were not
performed during the baseline procedure.
Quantitative coronary angiography
Coronary angiograms were analyzed offline using dedicated
bifurcation software (QAngioXA version 7.3, Medis, Leiden,
The Netherlands). Matched baseline, post-PCI and FU views
were selected from the available angiograms. The bifurcation
lesions were classified using the Medina classification [13].
All QCA analyses were performed in an end-diastolic frame,
after calibration using the contrast-filled guiding catheter.
Minimal lumen diameters (MLD) and lesion stenoses were
obtained at baseline, post-procedure and during FU. Acute
gain was calculated by subtracting the MLD at baseline from
the MLD post procedure. Late luminal loss (LLL) was cal-
culated by subtracting the MLD at FU from the MLD post
procedure. QCA analyses were performed both in-stent and
in-segment (in-stent plus 5 mm edges) for the following
segments: proximal MB, distal MB, SB, and for the ostial
(\3 mm from the carina) SB and distal MB.
Optical coherence tomography
OCT pullbacks were obtained using the Ilumien frequency-
domain system (St Jude Medical. St Paul, Minnesota, USA).
OCT imaging catheters were advanced over a conventional,
0.014-inch guidewire and pullbacks were performed during
continuous X-ray contrast injection of 4 ml/s at a maximum
pressure of 300 psi using an injection pump. Images were
acquired at 100 frames/s at a pullback speed of 20 mm/s.
After calibration using the reflection of the imaging catheter,
analyses of the acquired OCT images were performed offline
using the C7 system (St Jude Medical. St Paul, Minnesota,
USA). OCT analyses were performed separately in the fol-
lowing segments: distal MB, proximal MB, total SB (starting
from the carina), ostial SB (\3 mm from the carina), distal SB
([3 mm from the carina), and the MB bifurcation region. The
MB bifurcation region was further divided in a luminal half
‘toward the SB’ and a luminal half ‘opposite the SB’ (Fig. 1).
Analyses were performed in each third frame (0.6 mm
interval) for the proximal MB, distal MB, and SB segments,
whereas each frame (0.2 mm interval) was analysed for the
MB at the level of the SB segment. Luminal borders and stent
contours were traced manually in each analysed frame. The
NIH area was calculated by subtracting the lumen cross-
sectional area from the stent cross sectional area. The percent
NIH was calculated by dividing the NIH area by the stent area,
multiplied by 100. To assess for asymmetric stent expansion,
a stent eccentricity index was determined by dividing the
minimal stent diameter by the maximal stent diameter in each
frame, as previously described [14]. A per-strut analysis was
performed in each analysed frame. Strut apposition was
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considered incomplete if the distance from the endoluminal
stent surface to the vessel wall was greater than the thickness
of the strut (metal plus polymer, if applicable) in the distal
MB, total SB and MB bifurcation region, whereas in the
proximal MB, where Tryton and DES overlap, strut apposi-
tion was defined incomplete if the distance from the endolu-
minal cell surface to the vessel wall was greater than the strut
thickness of Tryton plus DES used. Struts were classified as
uncovered if any part of the strut was exposed to the lumen
with no visible tissue coverage. NIH thickness was measured
for every covered strut by measuring the distance from the
strut to the luminal border.
To evaluate NIH growth patterns within the Tryton SB
zone, mean per-strut NIH for each frame (in mm) was
plotted against the distance of the analysed frame from the
carina (in mm). Furthermore, the stent eccentricity index
was plotted against the distance from the carina (in mm) to
visually assess whether stent eccentricity influences growth
patterns within the SB zone of the Tryton stent.
Three-dimensional optical coherence tomography
reconstructions
Three-dimensional (3D) OCT images were reconstructed
offline using volume-rendering software (AMIRA soft-
ware, visualization science group, FEI company). SB ostia
were visually assessed from the patients in whom non-
apposed side branch (NASB) struts were seen during two-
dimensional OCT analyses. The 3D-OCT reconstructions
were used to assess the position of the NASB struts relative
to the SB ostium.
Results
Baseline patients and angiographic characteristics
Baseline patient and angiographic characteristics are
shown in Table 1. The majority (60 %) of the patients were
Fig. 1 Schematic drawing
illustrating the different regions
used for OCT analyses. At the
main branch (MB) bifurcation
region, cross sections were
analysed in two halves
separately: a luminal half
toward the side branch (SB),
and a luminal half opposite the
SB
Table 1 Baseline patient and angiographic characteristics
n = 10
Baseline clinical characteristics
Age 66 (± 9)
Male 6 (60 %)
Current smoker 1 (10 %)
Previous MI 2 (20 %)
Prior revascularization 2 (20 %)
Diabetes mellitus 2 (20 %)
Hypertension 3 (30 %)
Hypercholesterolemia 5 (50 %)
Indication for PCI
Stable angina 6 (60 %)
Unstable angina 1 (10 %)
NSTEMI 2 (20 %)
STEMI 1 (10 %)
Angiographic characteristics
Bifurcation location
Left main—RCx 1 (10 %)
LAD—diagonal branch 8 (80 %)
RCA—RDP 1 (10 %)
Medina classification (on QCA)
1, 1, 1 1 (10 %)
1, 0, 1 2 (20 %)
0, 0, 1 2 (20 %)
1, 1, 0 3 (30 %)
1, 0, 0 1 (10 %)
Lesion length (on QCA)
Proximal main branch (mm) 6.5 (±3.3)
Distal main branch (mm) 6.0 (±4.7)
Side branch (mm) 3.2 (±1.8)
Overall TIMI 3 flow 10 (100 %)
MI myocardial infarction, PCI percutaneous coronary intervention,
NSTEMI non ST-segment elevation myocardial infarction, STEMI
ST-segment elevation myocardial infarction, RCx ramus circumflex
artery, LAD left anterior descending artery, RCA right coronary artery,
RDP ramus descendens posterior, QCA quantitative coronary angi-
ography, TIMI thrombolysis in myocardial infarction
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male with a mean age of 66 years. Indication for PCI
included stable angina in 60 %, unstable angina in 10 %,
non ST-segment elevation myocardial infarction (NSTE-
MI) in 20 %, and ST-segment elevation myocardial
infarction (STEMI) in the remaining 10 %. Most bifurca-
tions were left anterior descending (LAD)—diagonal
branch bifurcations. One left main bifurcation lesion was
included in the current study.
Procedural characteristics and clinical outcomes
Procedural characteristics are summarized in Table 2. MB
and SB pre-dilatations were performed in most cases (80
and 90 %, respectively). Xience (Abbott Vascular, Inc.,
Illinois, USA) everolimus-eluting DES was used as MB
stent in 90 % of the cases, while in the remaining case no
MB stent was used. Final kissing balloon inflation was
performed in 90 % of the cases. In one case, SB wiring
through the MB stent was unsuccessful after multiple
attempts. None of the patients experienced any adverse
event since the Tryton implantation up to the repeat
angiography.
Quantitative coronary angiography
Mean time from PCI to FU angiography was
393 ± 103 days. QCA results are shown in Tables 3 and
4. In-stent acute gain was 1.78 ± 0.94, 1.18 ± 0.45, and
0.81 ± 0.42 mm in the proximal MB, distal MB and SB,
respectively, whereas in-stent acute gain was 1.14 ± 0.56
for the ostial distal MB and 0.93 ± 0.58 for the ostial SB.
In-stent LLL in the proximal MB, distal MB, and SB was
0.27 ± 0.31, 0.24 ± 0.28, and 0.49 ± 0.32 mm, respec-
tively (Fig. 2). Mean distal bifurcation angles were
54 ± 17, 51 ± 19, and 54 ± 16 degrees at baseline, post-
PCI and FU, respectively. Binary restenosis was found in
only one patient (SB stenosis of 57 % during FU). This
patient was asymptomatic and had no angina during
repeat angiography. No repeat intervention was
performed.
Optical coherence tomography
OCT pullbacks in the MB were obtained in all cases,
whereas OCT pullbacks in the SB could not be obtained in
4 cases due to kinking of the OCT catheter while
attempting to advance into the SB. OCT analyses are
summarized in Table 5.
Per strut analysis
In total, 6,127 struts were analysed in 515 frames. Only
0.7 % of total struts were uncovered, while 0.8 % of the
struts were incompletely apposed. The region with the most
incompletely apposed struts was the luminal half facing
toward the SB of the MB bifurcation region, with 6.2 % of
the struts being incompletely apposed in that region. Six-
teen percent of these struts were also uncovered with tissue
(Table 5).
Neointimal thickness
Average per-strut NIH thickness in the proximal MB, distal
MB and SB were 0.14 ± 0.11, 0.19 ± 0.11, and
0.34 ± 0.19 mm, respectively. NIH thickness in the MB
bifurcation region was comparable with the proximal en
distal MB segments (0.20 ± 0.14 opposite to the SB and
0.16 ± 0.13 mm towards the SB, respectively).
Patterns of neoitimal thickness in relation to the SB ostium
in individual patients
We observed differences between ostial and distal mean
NIH thickness in individual patients (Fig. 3). In two
patients, NIH thickness was smaller in the ostium of the SB
as compared with the distal SB (B and E), in two other
patients, there was no difference (C and D), whereas in the
remaining two patients NIH thickness was larger in the
ostium when compared with the distal SB (A and F). In
Fig. 4, the stent eccentricity index on the vertical axis was
plotted against the distances from the carina on the hori-
zontal axis showing stent eccentricity of the Tryton stent at
Table 2 Procedural characteristics
n = 10
Variable
MB predilatation 8 (80 %)
SB predilatation 9 (90 %)
Tryton used
3.0–2.5 9 19 mm 6 (60 %)
3.5–2.5 9 19 mm 3 (30 %)
3.5–3.0 9 18 mm 1 (10 %)
Main branch stent used
Xience prime 9 (90 %)
None 1 (10 %)
Diameter MB stent 3.0 (3.0–3.5)
Length MB stent 18 (13.5–28)
Additional stenting in target vessel 4 (40 %)
MB 3 (30 %)
SB 1 (10 %)
Final kissing balloon inflation 9 (90 %)
Post procedural TIMI 3 flow 10 (100 %)
MB main branch, SB side branch, TIMI thrombolysis in myocardial
infarction
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the SB ostium in some cases (B and E). In Fig. 5, the stent
eccentricity index of the most ostial SB frame (on the vertical
axis) was plotted against the ratios of NIH thickness of the
ostial versus distal SB (on the horizontal axis) showing that
ostial stent eccentricity is associated with NIH growth being
more pronounced distally in the SB.
Table 3 Pre- and post-procedural quantitative coronary angiography
Pre-procedure Post-procedure
MLD (mm)* RVD (mm) DS (%) MLD (mm) RVD (mm) DS (%) Acute gain (mm)* P value
In-stent
Proximal MB 1.15 (±0.67) 3.99 (±0.60) 69 (±18) 3.09 (±0.60) 3.85 (±0.59) 15 (±10) 1.78 (±0.94) 0.0005
Distal MB 1.21 (±0.60) 2.48 (±0.44) 51 (±21) 2.43 (±0.42) 2.63 (±0.59) 6 (±12) 1.18 (±0.45) 0.0002
SB 1.03 (±0.54) 2.15 (±0.27) 52 (±22) 1.92 (±0.30) 2.32 (±0.30) 16 (±9) 0.81 (±0.42) 0.0004
Ostium distal MB 1.50 (±0.64) 2.53 (±0.43) 40 (±25) 2.75 (±0.46) 2.74 (±0.29) -0.5 (±13) 1.14 (±0.56) 0.0007
Ostium SB 1.10 (±0.67) 2.18 (±0.29) 50 (±25) 2.09 (±0.33) 2.38 (±0.28) 12 (±13) 0.93 (±0.58) 0.0014
In-segment
Proximal MB 1.15 (±0.67) 3.99 (±0.60) 69 (±18) 2.90 (±0.70) 3.76 (±0.71) 17 (±11) 1.57 (±1.08) 0.0024
Distal MB 1.16 (±0.48) 2.43 (±0.40) 51 (±20) 1.89 (±0.20) 2.43 (±0.21) 21 (±11) 0.76 (±0.60) 0.0095
SB 1.00 (±0.52) 2.11 (±0.34) 52 (±22) 1.72 (±0.43) 2.17 (±0.36) 20 (±11) 0.64 (±0.44) 0.0023
MB main branch, SB side branch, MLD minimal lumen diameter, DS diameter stenosis
* Measurements/calculations based on 9 angiographies (from 1 patient, the software was unable to trace luminal borders and applying the
bifurcation algorithm correctly)
 Mean MLD based on 10 angiographies
Table 4 FU quantitative
coronary angiography
MB main branch, SB side
branch, MLD minimal lumen
diameter, DS diameter stenosis
MLD (mm) RVD (mm) DS (%) Late luminal loss (mm) P value
In-stent
Proximal MB 2.81 (±0.56) 4.42 (±0.70) 21 (±11) 0.27 (±0.31) 0.0022
Distal MB 2.19 (±0.49) 2.57 (±0.31) 15 (±12) 0.24 (±0.28) 0.0345
SB 1.43 (±0.33) 2.15 (±0.26) 33 (±14) 0.49 (±0.32) 0.0009
Ostium distal MB 2.47 (±0.53) 2.70 (±0.30) 9 (±15) 0.27 (±0.26) 0.0131
Ostium SB 1.51 (±0.38) 2.17 (±0.25) 30 (±15) 0.58 (±0.38) 0.0010
In-segment
Proximal MB 2.73 (±0.57) 4.38 (±0.79) 23 (±11) 0.18 (±0.34) 0.1335
Distal MB 2.00 (±0.37) 2.46 (±0.24) 18 (±11) -0.10 (±0.41) 0.4833
SB 1.42 (±0.32) 2.14 (±0.27) 33 (±14) 0.30 (±0.37) 0.0307
Fig. 2 Cumulative incidence curves of minimal lumen diameters (MLD) of the proximal main branch, distal main branch, and side branch
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Three-dimensional optical coherence tomography
Three-dimensional OCT images from the patients in
whom NASB struts were seen during 2D-OCT analyses
are shown in Fig. 6. While viewing at the SB ostia from
outside the vessel and from an endoluminal point-of-view
downstream, there were no stent struts clearly visualized
which obstructed the SB ostium. After rotating the 3D-
recontruction in such way that the NASB struts are best
visible, which was a perpendicular view at the SB ostium
in all cases, it could be clearly demonstrated that the
NASB struts are situated at the distal end of the SB ostia,
at the (neo-) carina. In two patients, these NASB struts
separated the SB ostia in two separate compartments,
while in the other 4 patients only a single compartment
was seen.
Discussion
Our study provides detailed information on neo-intimal
growth patterns of the Tryton bifurcation treatment.
Overall, QCA and OCT analyses demonstrated good
healing of the proximal and distal MB with an in-stent
LLL of 0.27 ± 0.31 and 0.24 ± 0.28 mm, respectively
and NIH thickness during FU of 0.14 ± 0.11 and
0.19 ± 0.11 mm, respectively, while healing of the SB is
less favourable with a LLL of 0.49 ± 0.32 mm and a
mean NIH thickness of 0.34 ± 0.19 mm. Furthermore,
3D-OCT reconstructions of the SB ostia of patients with
jailed SB struts demonstrated that the jailed SB struts
were situated only at the distal end of the ostia, at the
carinal level.
Previous angiographic follow-up studies
Up-to-date, two previous studies with angiographic FU
have been performed with the Tryton SB stent. While the
Tryton first-in-man study showed in-stent LLL of 0.25, 0.0,
and 0.17 mm in the proximal MB, distal MB, and SB
respectively [5], the PYTON study demonstrated con-
trasting results, showing in-stent LLL of 0.34, 0.29, and
0.57 mm, respectively [15]. Our findings are comparable
with this latter study, showing in-stent LLL of 0.27, 0.24,
and 0.49 mm, respectively. Although these findings might
be interpreted as unfavourable compared with historical
data from clinical trials on the Xience stent showing in-
stent LLL of 0.10–0.19 mm [16–19], they are not dissim-
ilar to QCA results of a substudy in complex lesions,
including bifurcation lesions, from one of the large trials on
Xience DES showing a LLL of 0.23 ± 0.44 mm [20].
Although the largest LLL was seen in the bare-metal
Tryton SB part, the LLL of 0.49 mm in fact compares very
well with historical data on straight, tubular BMS showing
LLL of 0.70–1.00 [21–24]. The relative low LLL we found
in the current study might be explained by the fact that only
*7 mm of the Tryton stent is positioned in the SB, while
the occurrence of BMS in-stent restenosis is inversely
related to lesion length [25].
Previous optical coherence tomography follow-up
studies
Until now, the above-mentioned PYTON study was the
only study published to-date, which evaluated the Tryton
treatment with intravascular imaging during FU. The
investigators of this study used OCT to assess strut
Table 5 One-year OCT analyses (n = 10)
Total Proximal MB Distal MB SB* Bifurcation
area: opposite SB
Bifurcation
area: toward SB
Per frame analysis: (n = 515) (n = 187) (n = 257) (n = 71)
Stent area (mm2) 7.84 (±2.26) 9.56 (±2.06) 7.43 (±1.47) 4.75 (±0.74)
Lumen area (mm2) 6.24 (±2.52) 8.15 (±2.42) 5.86 (±1.35) 2.56 (±0.73)
NIH area (mm2) 1.57 (±0.89) 1.36 (±0.98) 1.54 (±0.72) 2.23 (±0.89)
Percent NIH area (%) 0.22 (±0.15) 0.15 (±0.12) 0.21 (±0.09) 0.46 (±0.16)
Per strut analysis: (n = 6127) (n = 2155) (n = 2495) (n = 534) (n = 424) (n = 519)
NIH thickness (mm) 0.18 (±0.13) 0.14 (±0.11) 0.19 (±0.11) 0.34 (±0.19) 0.20 (±0.14) 0.16 (±0.13)
Uncovered struts (%) 41 (0.7) 8 (0.4) 3 (0.1) 0 (-) 16 (3.8) 14 (2.7)
Incomplete apposed struts (%) 50 (0.8) 12 (0.6) 6 (0.2) 0 (-) 0 (-) 32 (6.2)
Percentage uncovered from
incompletely apposed struts (%)
5 (10) 0 (-) 0 (-) NA NA 5 (16)
MB main branch, SB side branch, NIH neo-intimal hyperplasia, NA not applicable
* Based on 6 pullbacks
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apposition and coverage for the different segments. Our
findings were similar to their findings in that most uncov-
ered and incompletely apposed struts were at the bifurca-
tion region, whereas none of the struts in the SB were
unapposed or uncovered. While the PYTON investigators
did not distinguish between struts opposing the SB ostium
and struts facing the SB ostium, we found that all of the
unapposed struts in the MB bifurcation region were located
facing towards the SB. Interestingly, no incompletely
apposed struts were observed opposite from the SB ostium,
which has been shown with culotte stenting using
conventional DES after final kissing balloon inflation (the
so-called ‘napkin ring’ effect) [26, 27]. It could be
hypothesized that the open cell design of the Tryton stent
prevents this napkin ring effect since the large cell size of
Tryton in the MB zone does not limit MB DES expansion.
On contrary to PYTON, we also performed a per-strut
analysis regarding NIH thickness. The latter analysis has
not been performed by PYTON investigators and in that
respect it is a novel finding. We demonstrated a NIH
thickness of 0.14 and 0.19 mm in the proximal and distal
MB. These results compare well with previous OCT
Fig. 3 Mean neo-intimal hyperplasia (NIH) thickness per analysed
frame (vertical axis), plotted against the distance of the frame from
the carina (horizontal axis). Each letter a–f indicating an individual
patient. The dotted line indicates a 3 mm distance from the carina.
P values are between mean NIH of the first 3 mm versus mean NIH
beyond 3 mm from the carina. The lines in panel D illustrating
missing values due to OCT images of insufficient quality, whereas in
the other patients (a–c; e–f), the whole Tryton could be visualized
with OCT
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studies on the Xience stent in non-bifurcation studies,
which showed a NIH thickness of 0.10–0.18 mm [28–31].
Furthermore, the SB NIH of 0.34 mm we found resembles
the historical data evaluating BMS with OCT which con-
sistently showed NIH thickness of *0.35 mm [32, 33].
Neo-intimal growth patterns of the side branch
We explored the NIH growth patterns of the bare-metal SB
by plotting the mean NIH of each frame against the distance
from the carina (Fig. 3). It seems that there is some variation
in NIH growing patterns of the SB, although we have to be
cautious to draw general conclusions based on the relative
small sample size. We hypothesized that stent eccentricity at
the SB ostium might influence the NIH growth more distally
by disturbing flow patterns at the SB ostium. Indeed, we
found that in the patients with more pronounced distal NIH
growth, the most ostial stent contour was eccentric com-
pared with the other growth patterns (Fig. 4), These findings
need to be confirmed in a larger patient population.
Fig. 4 Stent eccentricity index (vertical axis), plotted against the
distance of the frame from the carina (horizontal axis). Each letter a–
f indicating an individual patient. A stent eccentricity index of 1
corresponds to a perfect round stent shape, whereas a ratio below 1
suggests an eccentric stent shape. The lines in panel D illustrating
missing values due to OCT images of insufficient quality, whereas in
the other patients (a–c; e–f), the whole Tryton could be visualized
with OCT
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Interestingly, the patient with the most pronounced ostial
NIH growth (patient ‘‘A’’ in Figs. 3 and 4), was the one
patient who did not receive a stent in the MB, suggesting that
drug from the MB stent does also influences NIH growth in
the ostial SB part of Tryton.
Non-apposed side branch struts
As mentioned above, most of the incompletely apposed
struts were found at the bifurcation region in the luminal
half facing toward the SB. Most of these struts are NASB
struts, jailing the SB on 2D-OCT. We performed 3D-OCT
reconstructions to assess where these NASB struts are
located relative to the SB ostium. We found that all of these
NASB struts are located at the distal end of the SB ostium
(at the carina), whereas none of the unapposed struts
toward the SB could be visualized at the proximal side of
the SB ostium, both with conventional 2D-OCT analyses as
well as with visual assessment of 3D-OCT reconstructions.
With 3D-OCT, we could visualize the shape of the NASB
struts. When placed correctly, the transition zone of the
Tryton stent should be positioned at the level of the carina.
This zone consists of three panels connecting the undu-
lating fronds in the MB with the zig-zag hoops more dis-
tally in the SB. Visual assessment of the shape of the
NASB struts showing the typical zig-zag shaped appear-
ance of the Xience hoops which implies that these NASB
struts belong to the Xience DES in the MB rather than the
Tryton stent. Indeed, no NASB struts were found in the one
patient who did not receive a MB stent. This suggests
NASB struts in the Tryton procedure could be attributed to
the MB stent and that re-crossing the most distal cell before
final kissing balloon inflation is also vital in Tryton pro-
cedures as it is in other bifurcation treatment strategies
[34–36], in order to minimize the amount of NASB struts
which are associated with delayed healing [37].
Drug-coating the Tryton stent, is it a useful future
development?
Our data showed that NIH growth within the SB is as could
be expected from a BMS, showing equal results compared
with historical QCA and OCT data on straight tubular
BMS. It is therefore an attractive concept whether clinical
outcomes could potentially improve further by drug-coat-
ing the bare-metal Tryton device, since drug-elution of
conventional tubular stents has shown to improve clinical
efficacy, especially with regard to in-stent restenosis [21].
Hypothesis-generating findings on the NIH distribution
from the current study might be helpful in the decision if
and where precisely to coat the Tryton stent with a drug in
the future. First, our data showed that in patients receiving
a DES in the MB, NIH growth in the SB ostium (\3 mm
from the carina) was quite modest, ranging from 0.25 to
0.41 mm. NIH thickness was more pronounced in the distal
SB, ranging from 0.19 up to as high as 0.61 mm. Second,
none of the struts in the SB were incompletely apposed or
uncovered. This may explain the excellent safety profile of
the stent with low ST rates, as observed in previous
observational studies [5–9]. Third, we found that all non-
apposed struts in the bifurcation region were located
toward the SB and with 3D-OCT we observed that all of
these struts were located at the carina. Of these struts, 16 %
were uncovered, which confirms the findings of a previous
autopsy study demonstrating impaired healing at the carina
with DES [10]. It is likely that two DES in close proximity
at the carina would impair healing even more, resulting in
an increased risk of stent thrombosis, as shown in a recent
meta-analysis comparing one with two DES used in
bifurcation treatment [11]. In conclusion, if it were to be
decided that Tryton will be coated with a drug, one might
argue only to coat the distal SB zone rather than the whole
stent, including the transition zone, to avoid a potential
increased risk of ST due to two DES in close proximity at
the carina impairing healing at the flow divider where flow
is the highest, and thereby slowing the healing process.
Study limitations
We investigated a relative small patient population. How-
ever, this study provides detailed per-strut information on
Fig. 5 Relation between the stent eccentricity index of the first side
branch (SB) frame (at the level of the carina) on the vertical axis and
the ratio of ostial (\3 mm from carina) versus distal ([3 mm from
carina) mean neo-intimal hyperplasia (NIH) thickness in the SB (in
mm) on the horizontal axis. An ostial-to-distal SB NIH ratio \1
indicates more NIH growth distally, whereas an ostial-to-distal SB
NIH ratio [1 indicates more NIH growth in the ostium
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healing responses of the Tryton treatment. Nevertheless,
due to the small sample size generalizability is limited and
the current findings should be interpreted with caution and
appreciated as hypothesis-generating. Initial Tryton
implantation was performed according to the operator’s
discretion and patients who already received a repeat PCI
of the Tryton-treated bifurcation lesion before 9 months
were excluded for the current study, and thus a selection
bias has been introduced. The current findings should be
appreciated as hypothesis-generating and its relation with
clinical outcomes should be investigated in large clinical
trials. Furthermore, we were not able to advance an OCT
catheter in the SB in 4 from the 10 patients, which might
introduce a selection bias for the OCT SB analyses.
Finally, baseline (both pre-procedural and post-procedural)
OCT imaging was not performed, which would have given
Fig. 6 Three-dimensional optical coherence tomography (3D-OCT)
reconstructions illustrating the position of incompletely apposed struts
relative to the side branch ostium. Panels horizontal from each other
correspond with the same patient. In the most left panels, OCT still
frames illustrating the incompletely apposed struts in the bifurcation
region facing toward the side branch. The second left panels showing
ostial views from outside the vessel. The third left panels showing
‘fly-through’ views looking downstream at the carina. In these
particular views, no struts were visualized which clearly obstructing
the side branch ostium. The second right frames showing the views
with the most optimal visualization of the non-apposed struts toward
the side branch, which was best visualized perpendicular to the side
branch ostium in all cases. The blue lines in the most right frames
illustrating the shape of the non-apposed struts, which were typical
‘zig-zag’ hoops in all cases. (*) illustrates guidewires, whereas (§)
illustrates guide wire shadows
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more insights in technical aspects during placement and its
relation to vascular healing at FU.
Conclusions
We found good vascular healing of the distal and proximal
part of the MB DES. Healing of the bare-metal Tryton in
the SB was less favourable compared to the MB DES,
although at least comparable with historical data on healing
of tubular BMS stents. The late loss of 0.49 mm in the SB
limits the systematic use of Tryton in all bifurcations,
especially in smaller side branches. Further, we found that
most incompletely apposed and uncovered struts are loca-
ted in the bifurcation region facing towards the SB ostium,
and that these struts are located distal (near the carina)
rather than proximal relative to the SB ostium.
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